louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03538002: The Effect of Blue-light Filtering Spectacle Lenses on Myopia Progression in Schoolchildren
Official title: Does Blue-light Filtering Spectacle Lens Promote Myopia Progression in Schoolchildren
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Myopia
Keywords: blue light filtering spectacle lens
Lead sponsor: The Hong Kong Polytechnic University
Sponsor class: OTHER
First posted: 2018-05-25
Enrollment: 148
Sex: ALL
Minimum age (years): 8
Maximum age (years): 13
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to investigate if the blue-light filtering spectacle lenses promote myopia progression in schoolchildren.

Detailed description: The effect of blue light on ocular health has been studied extensively. Shorter wavelength such as blue light could cause damage to the retina. The damage was more evident in the ageing eye. Since the tablets and mobile with blue LED backlight display are widely used, thus blue-light filtering spectacle lenses are now available in the market. However, whether this kind of lenses could affect the eye growth in schoolchildren is unknown. This study is then designed to investigate if the blue-light filtering spectacle lenses affect myopia progression in Hong Kong Chinese schoolchildren. The schoolchildren will be randomly allocated to either blue-light filtering spectacle lens group (treated) or conventional spectacle lens group (control). Their axial length and refraction will be monitored every 6 months for 2 years. The changes between two group will then be compared.

Eligibility criteria: Inclusion Criteria:

* Refraction: myopia of -1.00 dioptres (D) to -5.00D
* Astigmatism: equal or less than -1.50D
* Anisometropia: equal or less than 1.00D
* Best corrected monocular visual acuity: 0.0 LogMAR or better after full correction
* Parents' understanding and acceptance of random allocation of grouping

Exclusion Criteria:

* any ocular and systemic abnormalities might affect visual functions or refractive development
* prior treatment of myopic control, e.g. drugs, orthokeratology, progressive addition lenses, bifocal lenses, drugs (e.g. atropine), etc.

Primary outcomes:
measure: Cycloplegic refraction
timeFrame: 2 years
Secondary outcomes:
measure: Axial length
timeFrame: 2 years
Other outcomes:
Locations:
city: Hong Kong
country: Hong Kong
facility: Centre of Myopia Research, School of Optometry, The Hong Kong Polytechnic University
Study officials:
affiliation: Centre for Myopia Research, The Hong Kong Polytechnic University
name: Ka Man Chun, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03207802: Remotely Monitoring Patients With Chronic Conditions in Their Home
Official title: Necklace-Shaped Sensor for Non-Invasive Measurement of Vital Signs, Thoracic Impedance, ECG, Skin Temperature and Motion
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: CHF
Lead sponsor: Baxter Healthcare Corporation
Sponsor class: INDUSTRY
First posted: 2017-07-05
Enrollment: 36
Sex: ALL
Minimum age (years): 22
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients receiving home health care with one or more chronic diseases including CHF

Brief summary: Study will collect data from the home using the CoVa Monitoring System. Data will be captured and retrospectively analysis to determine if the data provided can alert clinician about a patient's declining health.

Detailed description: Study will collect data from the home using the CoVa Monitoring System. Data will be captured and retrospectively analysis to determine if the data provided can alert clinician about a patient's declining health. Data from the CoVa Monitoring System will be compared against electronic health records to determine if the data captured will provide insight into a patient's overall health. Additionally, user compliance will be monitored

Eligibility criteria: Inclusion Criteria:

* Chronic Disease including CHF
* Currently receiving home health care
* Recent discharge for a CHF event

Exclusion Criteria:

* Skin reaction to electrodes
* Inability to take measurements due to low BMI

Primary outcomes:
measure: Data correlation
timeFrame: 2-6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Texarkana
country: United States
facility: Elite Home Health
state: Arkansas
Study officials:
References:
Clinical trial NCT06195202: Serum Estradiol (E2) Levels in Breast Cancer Patients During Endocrine Therapy by High Performance Liquid Chromatography-tandem Mass Spectrometry (LC-MS /MS)
Official title: A Prospective Cohort Study of Serum Estradiol (E2) Levels in Breast Cancer Patients During Endocrine Therapy by High Performance Liquid Chromatography-tandem Mass Spectrometry (LC-MS /MS)
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Breast Cancer
Keywords: LC MS/MS
estradiol
Lead sponsor: Sun Yat-sen University
Sponsor class: OTHER
First posted: 2024-01-08
Enrollment: 2000
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 2023.9-2024.68 Breast cancer patients who received aromatase inhibitor (AIs) or fulvestrant (FUL) endocrine therapy in Sun Yat-sen University Cancer Center and need to test hormone levels.

Brief summary: The investigators intend to conduct a prospective cohort study to detect E2 levels during endocrine therapy in Chinese breast cancer patients using LC-MS/MS methods, and to determine the proportion of patients with premenopausal E2 levels (OFR or E2 insufficiency) during AIs or FUL endocrine therapy. To further explore the correlation between serum E2 levels and the efficacy of endocrine therapy in Chinese patients, so as to ensure the safety and efficacy of endocrine therapy for patients, and pave the way for further providing more accurate individualized treatment programs.


Eligibility criteria: Inclusion Criteria:

* Over 18 years old;
* Histologically confirmed breast cancer;
* Patients with early breast cancer (including natural menopause and artificial menopause using LHRHa), or patients with advanced breast cancer (including natural menopause and artificial menopause using LHRHa) who use AIs (letrozole, anastrozole or exemestane) as adjuvant endocrine therapy, First-line CDK4/6 inhibitors (Palbociclib, Dalpiciclib, Abemaciclib or Ribociclib) +AI endocrine therapy, second-line CDK4/6 inhibitors (Palbociclib, Dalpiciclib, Abemaciclib or Ribociclib) + fluvestrant (FUL) endocrine therapy;
* Patients with needs for hormone testing;
* Standard treatment, complete clinical data, including complete efficacy evaluation and follow-up data.

Exclusion Criteria:

* Breast cancer patients using TAM endocrine therapy;
* In advanced patients, AIs exceeded first-line use (that is, in advanced disease, one endocrine therapy regimen had been used and failed), and FUL exceeded second-line use (that is, more than one endocrine therapy regimen had been used and failed)

Primary outcomes:
measure: The serum E2 levels in breast cancer patients during endocrine therapy.
timeFrame: From enrollment to 1 months
Secondary outcomes:
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Sun Yat-sen University Cancer Center
state: Guangdong
Study officials:
References:
Clinical trial NCT01255202: The Prediction of Preeclampsia/Toxemia in Twin Pregnancy
Official title: Prospective Longitudenal Study in the Prediction of Preeclampsia/Toxemia in Twin Pregnancy
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Preeclampsia/Toxemia
Keywords: preeclampsia
toxemia
twin
pregnancy
pp13
prediction
kongo red
Lead sponsor: Assaf-Harofeh Medical Center
Sponsor class: OTHER_GOV
First posted: 2010-12-07
Enrollment: 200
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: women with twin preganacy undergoing nuchal scan in our department

Brief summary: The purpose of this study is to finout whetere uterinae artery flow , PP13 and endogolin levels in the serum and kongo red in the urine can predict preeclamsia toxemia in twin pregnancies.


Eligibility criteria: Inclusion Criteria:

* a women with a vaiable twin pregnany

Exclusion Criteria:

* women with thrombophilya
* women terated with anticoagolant
* women with vascular disease

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Zrifin
country: Israel
facility: Assaf Harofe Medical Center
Study officials:
References:
Clinical trial NCT01818102: CT Window Setting to Select Double-lumen Tube Size
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Bronchial Cuff Volume at Air-tight Seal
Intracuff Cuff Pressure at Air-tighe Seal
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2013-03-26
Enrollment: 228
Sex: ALL
Minimum age (years): 20
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to investigate the appropriate window setting of chest computed tomography to select a correct size of double-lumen endobronchial tube.


Eligibility criteria: Inclusion Criteria:

* Patients undergoing thoracic surgery that require the placement of left-sided double-lumen tubes

Exclusion Criteria:

* Abnoraml anatomy of tracheobronchail tree
* Intraluminal lesion in the left mainstem bronchus
* Anticipated difficult intubation

Primary outcomes:
measure: Air-leak at deflation of bronchial cuff
timeFrame: An expected average of 10 min after double lumen tube intubation
measure: Air-tight seal below resting volume of bronchial cuff
timeFrame: An expected average of 10 min after double lumen tube intubation
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
Study officials:
References:
Clinical trial NCT02966002: Aspirin as a Novel Anti-Inflammatory Modality in the Fontan Patients
Official title: Aspirin as a Novel Anti-Inflammatory Modality in the Fontan Patients
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE4
Conditions: Fontan Procedure
Lead sponsor: University of Michigan
Sponsor class: OTHER
First posted: 2016-11-17
Enrollment: 9
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Patients who have undergone the Fontan procedure (a congenital heart surgery) may develop complications many years after their operation. Studies have shown that some of these patients develop an ongoing inflammatory state, which may be the cause of these late complications. Aspirin is a common over the counter anti-inflammatory medication used for many other chronic diseases. This study may help determine if aspirin therapy can limit the inflammation seen in Fontan patients and prevent these late complications.


Eligibility criteria: Inclusion Criteria:

* Adults who have Fontan repair of single ventricle

Exclusion Criteria: Persons with the following history, conditions, or behavior will be excluded

* Active protein losing enteropathy within the past three years
* Congestive heart failure
* Active arrhythmias
* Taking Coumadin (Warfarin)
* Bleeding disorder
* Known esophageal varicies
* Consuming more than 10 alcoholic drinks per week.
* Pregnant
* Planning to become pregnant

Primary outcomes:
measure: Change in Total Cholesterol
timeFrame: 8 weeks
measure: Change in HDL (High-Density Lipoprotein)-Cholesterol
timeFrame: 8 weeks
Secondary outcomes:
measure: High Sensitivity CRP(C-Reactive Protein)
timeFrame: 8 weeks
measure: Quality of Life
timeFrame: 8 weeks
Other outcomes:
Locations:
city: Ann Arbor
country: United States
facility: University of Michigan
state: Michigan
Study officials:
affiliation: University of Michigan
name: Adam Lubert, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01497002: Comparison of the OSHO Protocol to a Standard Arm Protocol of the German AML Intergroup in Patients With AML>60a
Official title: Randomized Phase III Study Comparing the OSHO Arm to the Standard Intergroup Arm.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Acute Myeloid Leukaemia
Keywords: AML
Lead sponsor: University of Leipzig
Sponsor class: OTHER
First posted: 2011-12-22
Enrollment: 1222
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Improvement of the treatment-results in elderly patients with acute myeloid leukemia through intensification of consolidation chemotherapy and/or allografting as consolidative immunotherapy

Detailed description: Measuring EFS depending on induction therapy

Eligibility criteria: Inclusion Criteria:

* Patients of both sexes with age \> 60 years and newly diagnosed acute myeloid leukaemia as defined by new WHO classification
* written informed consent

Exclusion Criteria:

* pretreatment of leukemia
* no informed consent
* simultaneous inclusion in other studies
* mental disability
* contraindication for intensive chemotherapy
* AML FAB M3
* contraindication for allogeneic stem cell transplantation
* restriction of following organ functions:
* creatinine-clearance \< 50 ml/min
* cardiac ejection fraction \< 40 %
* severe pulmonary restriction
* bilirubin \> 2x ULN; SGOT and SGPT \> 4x ULN
* uncontrolled hypertension
* severe uncontrolled metabolism disturbance
* Karnofsky-performance-score \< 70%
* hepatitis C
* other malignancy
* age of unrelated donor \>70 years and age of related donor \>75 years

Primary outcomes:
measure: Event free survival
timeFrame: after 5 years
Secondary outcomes:
measure: OS
timeFrame: at 5 years
measure: LFS
timeFrame: at 5 years
Other outcomes:
Locations:
city: Leipzig
country: Germany
facility: University of Leipzig, Hematology
Study officials:
affiliation: University of Leipzig
name: Dietger Niederwieser, Prof.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06491602: A Study of Clinical Characteristics ,Risk Factors and Outcome of Lupus Nephritis Among Children With Systemic Lupus Erthromatousus in Sohag Univeristy Hospital
Official title: A Study of Clinical Characteristics ,Risk Factors and Outcome of Lupus Nephritis Among Children With Systemic Lupus Erthromatousus in Sohag Univeristy Hospital
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Lupus Nephritis
Lead sponsor: Sohag University
Sponsor class: OTHER
First posted: 2024-07-09
Enrollment: 30
Sex: ALL
Minimum age (years): 1
Maximum age (years): 18
Standard ages: CHILD
ADULT
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: all children with diagnostic criteria of SLE atteding to pediatric rheumatology and immunology clinic

Brief summary: systemic lupus erthrematosus is an inflamatory and autoimmune condition characterized by multisystem affection and chronic course with unpredictable flares despite potentially afffecting every oragan . kidney involvment are the most common


Eligibility criteria: Inclusion Criteria:

- aim to include all children fulfilling diagnostic criteria

Exclusion Criteria:

* children with other rheumatological disorder neonates chidren with other nephrolgy disorder

Primary outcomes:
measure: remission of LN
timeFrame: 1 year
measure: progress to CKD
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Sohag
country: Egypt
facility: Sohag university Hospital
Study officials:
References:
citation: Tsokos GC. Systemic lupus erythematosus. N Engl J Med. 2011 Dec 1;365(22):2110-21. doi: 10.1056/NEJMra1100359. No abstract available.
citation: Hiraki LT, Feldman CH, Liu J, Alarcon GS, Fischer MA, Winkelmayer WC, Costenbader KH. Prevalence, incidence, and demographics of systemic lupus erythematosus and lupus nephritis from 2000 to 2004 among children in the US Medicaid beneficiary population. Arthritis Rheum. 2012 Aug;64(8):2669-76. doi: 10.1002/art.34472.
citation: Demir S, Gulhan B, Ozen S, Celegen K, Batu ED, Tas N, Orhan D, Bilginer Y, Duzova A, Ozaltin F, Topaloglu R. Long-term renal survival of paediatric patients with lupus nephritis. Nephrol Dial Transplant. 2022 May 25;37(6):1069-1077. doi: 10.1093/ndt/gfab152.
citation: Hiraki LT, Benseler SM, Tyrrell PN, Hebert D, Harvey E, Silverman ED. Clinical and laboratory characteristics and long-term outcome of pediatric systemic lupus erythematosus: a longitudinal study. J Pediatr. 2008 Apr;152(4):550-6. doi: 10.1016/j.jpeds.2007.09.019. Epub 2007 Nov 5.
Clinical trial NCT01040702: The Effect of Methylphenidate on Decision-making Ability of Attention Deficit Hyperactivity Disorder (ADHD) Adults
Official title: The Effect of Methylphenidate on Decision-making Ability of ADHD Adults
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Attention Deficit Hyperactivity Disorder
Lead sponsor: Shalvata Mental Health Center
Sponsor class: OTHER
First posted: 2009-12-30
Enrollment: 58
Sex: ALL
Minimum age (years): 21
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: The aim of the study is to assess the effect of Methylphenidate on cognitive performance and decision-making ability of ADHD adults, and to compare this effect to the effect on healthy control adults.

Detailed description: Two matched groups of adults - with and without ADHD diagnosis - will perform a battery of computerized tasks assessing sustained attention,working-memory,non-verbal IQ,and decision-making ability. In each group,half of the participants will perform the tasks after receiving a capsule containing methylphenidate (MPH), and the other half will perform the tasks after receiving placebo. Task performance measures will then be compared in order to assess the effect of MPH on these domains.

Eligibility criteria: Inclusion Criteria:

* adults in the age of 21-50

Exclusion Criteria:

* pregnant or nursing women.
* people who suffer from a psychiatric disorder other than ADHD which could account for their inattention symptoms better than ADHD.
* people who lack judgment or are unable to communicate with the experimenters.
* people who are incapable of performing the computerized tasks due to sensory or motor disabilities.

Primary outcomes:
measure: score in decision-making task 1
timeFrame: by the end of the task
Secondary outcomes:
measure: working memory task score
timeFrame: by the end of the task
Other outcomes:
Locations:
city: Hod Hasharon
country: Israel
facility: cognitive laboratory,Shalvata MHC
Study officials:
affiliation: MD
name: Ziv Carmel, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00823602: Agonist Gonadotropin-Releasing Hormone (GnRH) Versus Antagonist GnRH
Official title: Comparison Between GnRH Agonist Long Protocol And GnRH Antagonist Protocol In Outcome Of The First Cycle ART
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Infertility
Keywords: GnRH antagonist
GnRH agonist
pregnancy rate
Ovarian stimulation
Lead sponsor: Yazd Research & Clinical Center for Infertility
Sponsor class: OTHER
First posted: 2009-01-15
Enrollment: 2
Sex: FEMALE
Maximum age (years): 35
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Literature suggests that GnRH antagonists are comparatively more often used in cycles which have an unfavorable prior prognosis, and this protocol is an ideal one for poor responder patients. Up to now, however not enough prospectives have been published to prove any beneficial effect of antagonists on the first cycle assisted reproductive technique.

This prospective study will do to evaluate the efficacy of gonadotropin releasing hormone antagonist in comparison with the standard long protocol in the first cycle of ART.

The investigators will randomize 160 patients undergoing ART for the first time . Group 1 (n=80) was stimulate with a standard long protocol and group 2 (n=80) stimulated with GnRH antagonist and then result of ART compare in two group .


Eligibility criteria: Inclusion Criteria:

* first cycle of ART
* age \< 35 years
* basal FSH \< 10 IU/L

Exclusion Criteria:

* previous IVF or ICSI, hyperprolactinemia, hyperthyroidism, hypothyroidism, uterine abnormality, severe endometriosis
* only one ovary

Primary outcomes:
measure: pregnancy rate
timeFrame: 2weeks
Secondary outcomes:
measure: ovarian stimulation
timeFrame: 10days
Other outcomes:
Locations:
city: Yazd
country: Iran, Islamic Republic of
facility: Yazd Research and Clinical Center For Infertility
Study officials:
affiliation: Yazd Research & Clinical Center for Infertility
name: razieh firouzabadi, MD
role: STUDY_CHAIR
References:
Clinical trial NCT00476502: Study of Genetic Polymorphisms in Thai HIV-1 Infected Patients on SQV/r
Official title: Study of Genetic Polymorphisms of CYP 3A and MDR-1 Genes in Thai HIV-1 Infected Patients on Saquinavir/Ritonavir
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: HIV Infections
Keywords: genetic polymorphism
CYP 3A
MDR-1
Thai
HIV
Treatment Experienced
Lead sponsor: The HIV Netherlands Australia Thailand Research Collaboration
Sponsor class: OTHER
Collaborators: name: Roche Pharma AG
First posted: 2007-05-22
Enrollment: 250
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: patients on stable SQV based HAART therapy

Brief summary: Study of genetic polymorphisms of CYP #A and MDR-1 genes in Thai HIV-1 infected patients on saquinavir/ritonavir.

Detailed description: Genetic polymorphisms will be investigated by polymerase-chain reaction (PCR) and drug levels of saquinavir will be determined by high phase liquid chromatography with UV-detected (HPLC).

Eligibility criteria: Inclusion Criteria:

* HIV-infected persons who have been enrolled in the Staccato study
* On low-dose ritonavir boosted saquinavir at the time blood samples are collected

Exclusion Criteria:

* Inability to understand the nature and extent of the study and the procedures required

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Bangkok
country: Thailand
facility: The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT)
Study officials:
affiliation: The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT)
name: Kiat Ruxrungtham, MD
role: PRINCIPAL_INVESTIGATOR
References: